Temporal trends in the clinical presentation of Graves' orbitopathy: a single-center retrospective study.

Clinical presentation Graves Hyperthyroidism Ophthalmopathy Severity

Journal

Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594

Informations de publication

Date de publication:
15 Mar 2024
Historique:
received: 04 05 2023
accepted: 07 02 2024
medline: 15 3 2024
pubmed: 15 3 2024
entrez: 15 3 2024
Statut: aheadofprint

Résumé

Graves' ophthalmopathy (GO) is an autoimmune disease that affects orbital soft tissues and represents the most common extrathyroidal manifestation of Graves' disease (GD). The European Group of Graves' Ophthalmopathy (EUGOGO) has attempted to shed light on the European epidemiological picture of GO, suggesting that GO in newly diagnosed patients in recent years has a trend towards a less severe clinical presentation. There are no studies that focus this issue on the population of our area; we aimed to evaluate the trend of GO clinical presentation in our outpatient clinic through an observation period of 10 years. We compared 55 consecutive patients, 11 males (F) and 44 females (M), who came to our observation from January 2005 to December 2006 [Group 1 (G1)], with 56 patients, 15 males, and 41 females, who were referred to us from 2015 to 2016 [Group 2 (G2)]. We studied the following putative predictors of GO presentation and severity: thyroid function, smoking, diabetes, hypercholesterolemia, time from GO diagnosis to referral to our thyroid centre (TGOD), sex and age. GO severity was significantly reduced in G2 vs. G1 (p = 0.04). TGOD ≥ 3 months was related to clinical characteristics of GO (severity and Clinical Activity Score ≥ 4) and was an independent predictor of GO severity (p = 0.01). The other variables evaluated had no independent effects. We found that GO severity at presentation was significantly reduced over a ten-year observation period (2005-2006 vs. 2015-2016) in GO patients referred to our tertiary thyroid centre. TGOD ≥ 3 months was an independent predictor of GO severity.

Identifiants

DOI: 10.1007/s40618-024-02332-3 PMID: 38488977
pubmed: 38488977
doi: 10.1007/s40618-024-02332-3
pii: 10.1007/s40618-024-02332-3
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Bahn RS (2010) Grave’s ophthalmopathy. N Engl J Med 362:726–738. https://doi.org/10.1056/NEJMra0905750
doi: 10.1056/NEJMra0905750 pubmed: 20181974 pmcid: 3902010
Lazarus JH, Marino M (2010) Orbit-thyroid relationship. In: Wiersinga WM, Kahaly GJ (eds) Graves’ orbitopathy—a multidisciplinary approach—question and answers. Karger, Basel, pp 26–32. https://doi.org/10.1159/000320425
Rapoport B, McLachlan SM (2007) The thyrotropin receptor in Graves’ disease. Thyroid 17:911–922. https://doi.org/10.1089/thy.2007.0170
doi: 10.1089/thy.2007.0170 pubmed: 17822379
Krieger CC, Place RF, Bevilacqua C, Marcus-Samuels B, Abel BS, Skarulis MC, Kahaly GJ, Neumann S, Gershengorn MC (2016) TSH/IGF-1 receptor cross talk in Graves’ ophthalmopathy pathogenesis. J Clin Endocrinol Metab 101:2340–2347. https://doi.org/10.1210/jc.2016-1315
doi: 10.1210/jc.2016-1315 pubmed: 27043163 pmcid: 4891793
Smith TJ, Janssen JAMJL (2017) Building the case for insulin-like growth factor receptor-I involvement in thyroid-associated ophthalmopathy. Front Endocrinol 7:1–8. https://doi.org/10.3389/fendo.2016.00167
doi: 10.3389/fendo.2016.00167
Krieger CC, Neumann S, Gershengorn MC (2020) TSH/IGF1 receptor crosstalk: mechanism and clinical implications. Pharmacol Ther 209:107502. https://doi.org/10.1016/j.pharmthera.2020.107502
doi: 10.1016/j.pharmthera.2020.107502 pubmed: 32061922 pmcid: 7187798
Perros P, Hegedüs L, Bartalena L, Marcocci C, Kahaly GJ, Baldeschi L, Salvi M, Lazarus JH, Eckstein A, Pitz S, Boboridis K, Anagnostis P, Ayvaz G, Boschi A, Brix TH, Currò N, Konuk O, Marinò M, Mitchell AL, Stankovic B, Törüner FB, Von Arx G, Zarković M, Wiersinga WM (2017) Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis 12:4–9. https://doi.org/10.1186/s13023-017-0625-1
doi: 10.1186/s13023-017-0625-1
Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marinò M, Vaidya B, Wiersinga WM (2021) The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol 185:G43–G67. https://doi.org/10.1530/EJE-21-0479
doi: 10.1530/EJE-21-0479 pubmed: 34297684
Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, Pariani N, Gallo D, Azzolini C, Ferrario M, Bartalena L (2013) Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab 98:1443–1449. https://doi.org/10.1210/jc.2012-3873
doi: 10.1210/jc.2012-3873 pubmed: 23408569
Bartalena L, Masiello E, Magri F, Veronesi G, Bianconi E, Zerbini F, Gaiti M, Spreafico E, Gallo D, Premoli P, Piantanida E, Tanda ML, Ferrario M, Vitti P, Chiovato L (2016) The phenotype of newly diagnosed Graves’ disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study. J Endocrinol Invest 39:1445–1451. https://doi.org/10.1007/s40618-016-0516-7
doi: 10.1007/s40618-016-0516-7 pubmed: 27465670
Perros P, Zarkovi M, Azzolini C, Ayvaz G, Baldeschi L, Bartalena L, Boschi A, Bournaud C, Brix TH, Covelli D, Iri S, Daumerie C, Eckstein A, Fichter N, Führer D, Hegedüs L, Kahaly GJ, Konuk O, Lareida J, Lazarus J, Leo M, Mathiopoulou L, Menconi F, Morris D, Okosieme O, Orgiazzi J, Pitz S, Salvi M, Vardanian-Vartin C, Wiersinga W, Bernard M, Clarke L, Currò N, Dayan C, Dickinson J, Knezevi M, Lane C, Marcocci C, Marinò M, Möller L, Nardi M, Neoh C, Pearce S, Von Arx G, Törüner FB (2015) PREGO (presentation of Graves’ orbitopathy) study: changes in referral patterns to European Group on Graves’ Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. Br J Ophthalmol 99:1531–1535. https://doi.org/10.1136/bjophthalmol-2015-306733
doi: 10.1136/bjophthalmol-2015-306733 pubmed: 25953846
Schuh A, Ayvaz G, Baldeschi L, Baretić M, Bechtold D, Boschi A, Brix TH, Burlacu M-C, Ciric J, Covelli D, Currò N, Donati S, Eckstein AK, Fichter N, Führer D, Horn M, Jabłońska-Pawlak A, Juri Mandić J, Kahaly GJ, Konuk O, Langbein A, Lanzolla G, Marcocci C, Marinò M, Miśkiewicz P, Beleslin BN, Pérez-Lázaro A, Pérez-López M, Ponto KA, Quinn A, Rudofsky G, Salvi M, Schittkowski MP, Tanda ML, Toruner F, Vaidya B, Hintschich CR (2023) Presentation of Graves’ orbitopathy within European Group On Graves’ Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III). Br J Ophthalmol 108:294–300. https://doi.org/10.1136/bjo-2022-322442
doi: 10.1136/bjo-2022-322442
Bartalena L (2011) The dilemma of how to manage Graves’ hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab 96:592–599. https://doi.org/10.1210/jc.2010-2329
doi: 10.1210/jc.2010-2329 pubmed: 21190983
Wiersinga W, Žarković M, Bartalena L, Donati S, Perros P, Okosieme O, Morris D, Fichter N, Lareida J, Von Arx G, Daumerie C, Christina Burlacu M, Kahaly G, Pitz S, Beleslin B, Ćirić J, Ayvaz G, Konuk O, Töröner FB, Salvi M, Covelli D, Curro N, Hegedös L, Brix T (2018) Predictive score for the development or progression of Graves’ orbitopathy in patients with newly diagnosed Graves’ hyperthyroidism. Eur J Endocrinol 178:635–643. https://doi.org/10.1530/EJE-18-0039
doi: 10.1530/EJE-18-0039 pubmed: 29650691
Träisk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J, Hallengren B, Hedner P, Lantz M, Nyström E, Ponjavic V, Taube A, Törring O, Wallin G, Åsman P, Lundell G, Lindstedt G, Michanek A, Norrsell K, Valdemarsson S, Garkavij M, Tennvall J, Widmark H, Stigmar G, Arwidi Å, Bjelkengren G, Hemdahl B, Jönsson H, Becker C, Freyschuss B, Hoffstedt J, Tullgren O, Wahrenberg H, Wennlund A, Röjdmark S, Sääf M, Thorén M, Hamberger B, Blomgren H, Hilding C, Hjelm Skog AL (2009) Thyroid-associated ophthalmopathy after treatment for Graves’ hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 94:3700–3707. https://doi.org/10.1210/jc.2009-0747
doi: 10.1210/jc.2009-0747 pubmed: 19723755
Žarković M (2012) The role of oxidative stress on the pathogenesis of Graves’ disease. J Thyroid Res 2012:302537. https://doi.org/10.1155/2012/302537
doi: 10.1155/2012/302537 pubmed: 22175033
Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM (2016) The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J 5:9–26. https://doi.org/10.1159/000443828
doi: 10.1159/000443828 pubmed: 27099835 pmcid: 4836120
Manji N, Carr-Smith JD, Boelaert K, Allahabadia A, Armitage M, Chatterjee VK, Lazarus JH, Pearce SHS, Vaidya B, Gough SC, Franklyn JA (2006) Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype. J Clin Endocrinol Metab 91:4873–4880. https://doi.org/10.1210/jc.2006-1402
doi: 10.1210/jc.2006-1402 pubmed: 16968788
Wiersinga WM (2013) Smoking and thyroid. Clin Endocrinol (Oxf) 79:145–151. https://doi.org/10.1111/cen.12222
doi: 10.1111/cen.12222 pubmed: 23581474
Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell’Unto E, Bartolomei MP, Nardi M, Martino E, Pinchera A (1998) Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med 129:632–635. https://doi.org/10.7326/0003-4819-129-8-199810150-00010
doi: 10.7326/0003-4819-129-8-199810150-00010 pubmed: 9786811
Cawood TJ, Moriarty P, O’Farrelly C, O’Shea D (2007) Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link. J Clin Endocrinol Metab 92:59–64. https://doi.org/10.1210/jc.2006-1824
doi: 10.1210/jc.2006-1824 pubmed: 17047020
Kau HC, Wu SB, Tsai CC, Liu CJL, Wei YH (2016) Cigarette smoke extract-induced oxidative stress and fibrosis-related genes expression in orbital fibroblasts from patients with Graves’ ophthalmopathy. Oxid Med Cell Longev 2016:4676289. https://doi.org/10.1155/2016/4676289
doi: 10.1155/2016/4676289 pubmed: 27340508 pmcid: 4909929
Tehrani H, Mahdizadeh M, Peyman N, Gholian-Aval M, Charoghchian Khorasani E, Jafari A (2022) Exploration factors on smoking among female adolescents based on the viewpoints of Iranian adolescent girls. BMC Womens Health 22:1–8. https://doi.org/10.1186/s12905-022-01791-1
doi: 10.1186/s12905-022-01791-1
Le Moli R, Muscia V, Tumminia A, Frittitta L, Buscema M, Palermo F, Sciacca L, Squatrito S, Vigneri R (2015) Type 2 diabetic patients with Graves’ disease have more frequent and severe Graves’ orbitopathy. Nutr Metab Cardiovasc Dis 25:452–457. https://doi.org/10.1016/j.numecd.2015.01.003
doi: 10.1016/j.numecd.2015.01.003 pubmed: 25746910
Lanzolla G, Vannucchi G, Ionni I, Campi I, Sileo F, Lazzaroni E, Marinò M (2020) Cholesterol serum levels and use of statins in Graves’ orbitopathy: a new starting point for the therapy. Front Endocrinol 10:1–8. https://doi.org/10.3389/fendo.2019.00933
doi: 10.3389/fendo.2019.00933
Naselli A, Moretti D, Regalbuto C, Arpi ML, Lo Giudice F, Frasca F, Belfiore A, Le Moli R (2020) Evidence that baseline levels of low-density lipoproteins cholesterol affect the clinical response of Graves’ ophthalmopathy to parenteral corticosteroids. Front Endocrinol 11:1–10. https://doi.org/10.3389/fendo.2020.609895
doi: 10.3389/fendo.2020.609895
Neag EJ, Smith TJ (2022) 2021 update on thyroid-associated ophthalmopathy. J Endocrinol Invest 45:235–259. https://doi.org/10.1007/s40618-021-01663-9
doi: 10.1007/s40618-021-01663-9 pubmed: 34417736
Laurberg P, Berman DC, Pedersen IB, Andersen S, Carlé A (2012) Incidence and clinical presentation of moderate to severe Graves’ orbitopathy in a Danish population before and after iodine fortification of salt. J Clin Endocrinol Metab 97:2325–2332. https://doi.org/10.1210/jc.2012-1275
doi: 10.1210/jc.2012-1275 pubmed: 22518849 pmcid: 3387399
Olivieri A, Vitti P (2014) Rapporti ISTISAN 14/6. ISSN, 1123–3127
Marinò M, Menconi F, Dottore GR, Leo M, Marcocci C (2018) Selenium in Graves hyperthyroidism and orbitopathy. Ophthal Plast Reconstr Surg 34:S105–S110. https://doi.org/10.1097/IOP.0000000000001136
doi: 10.1097/IOP.0000000000001136 pubmed: 29933354
Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga W (2011) Selenium and the course of mild Graves’ orbitopathy. N Engl J Med 364:1920–1931. https://doi.org/10.1056/nejmoa1012985
doi: 10.1056/nejmoa1012985 pubmed: 21591944

Auteurs

R Le Moli (R)

Department of Clinical and Experimental Medicine, Endocrinology Unit, Garibaldi Nesima Hospital, University of Catania, Via Palermo 636, 95125, Catania, Italy. rlemoli@unict.it.
ORCID: 0000-0002-1398-9271

A Naselli (A)

Department of Clinical and Experimental Medicine, Endocrinology Unit, Garibaldi Nesima Hospital, University of Catania, Via Palermo 636, 95125, Catania, Italy.

F Lo Giudice (FL)

Department of Clinical and Experimental Medicine, Endocrinology Unit, Garibaldi Nesima Hospital, University of Catania, Via Palermo 636, 95125, Catania, Italy.

G Costanzo (G)

Department of Clinical and Experimental Medicine, Endocrinology Unit, Garibaldi Nesima Hospital, University of Catania, Via Palermo 636, 95125, Catania, Italy.

F Frasca (F)

Department of Clinical and Experimental Medicine, Endocrinology Unit, Garibaldi Nesima Hospital, University of Catania, Via Palermo 636, 95125, Catania, Italy.

A Belfiore (A)

Department of Clinical and Experimental Medicine, Endocrinology Unit, Garibaldi Nesima Hospital, University of Catania, Via Palermo 636, 95125, Catania, Italy.

Classifications MeSH